Create
Log in
Enquire now
Eiger BioPharmaceuticals
A biopharmaceutical company developing drugs for the treatment of rare diseases
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Organization
Company
AngelList URL
angel.co/eiger-biop...maceuticals
B2X
B2C
0
B2B
0
Board of Directors
David Cory
0
Christine Murray
0
Amit K. Sachdev
0
David Apelian
0
CAGE Code
4VVJ0
0
CEO
David Cory
0
CIK Number
1,305,253
0
Legal Name
Eiger BioPharmaceuticals, Inc.
Company Operating Status
Active
Country
United States
0
Crunchbase URL
crunchbase.com/organiz...euticals
DUNS Number
786243613
0
Email Address
Sign up to view
0
Facebook URL
@Eiger-BioPharmaceuticals-116014218895858
Fax Number
1-650-618-1621
0
Founded Date
January 1, 2008
Full Address
2155 Park Boulevard Palo Alto, CA 94306, USA
0
Headquarters
California
Industry
Biology
Biotechnology
Biomedical engineering
Synthetic chemistry
Engineering
Technology
Investors
Vivo Ventures
InterWest Partners
IRS Number
330,971,591
Latest Funding Round Date
April 2016
Latest Funding Round Amount (USD)
3,000,000
Latest Funding Type
Series A
LinkedIn URL
@company/eiger-biopharmaceuticals-inc.
Location
San Carlos, California
Palo Alto, California
0
United States
San Francisco
Number of Employees
51
0
Number of Employees (Ranges)
11 – 50
0
Patents Assigned (Count)
6
Phone Number
Sign up to view
0
Pitchbook URL
pitchbook.com/profiles.../52943-23
Place of Incorporation
Delaware
Previous Name
Celladon Corp
0
SIC Code
2,836
0
Exchange
Nasdaq
0
Stock Symbol
EIGR
0
Ticker Symbol
EIGR
Total Funding Amount (USD)
74,797,412
Official Website
eigerbio.com
Wellfound ID
eiger-biopharmaceuticals
Wikidata ID
Q30268946
Find more companies like Eiger BioPharmaceuticals
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Pricing
Enterprise
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE